

Assessment of CD4⁺CD28^{null} T- Lymphocytes in Pediatric Patients with Sickle Cell Disease

Thesis

*Submitted for Partial Fulfillment of M. Sc. Degree
in Pediatrics*

Prepared by

Aya Sayed Saad Sayed ElBalasy

M.B, B.Ch, 2013

Faculty of Medicine - M.U.S.T. University

Supervised by

Prof. Mohsen Saleh ElAlfy

Professor of Pediatrics

Faculty of Medicine - Ain Shams University

Dr. Fatma Soliman Elsayed Ebeid

Lecturer of Pediatrics

Faculty of Medicine - Ain Shams University

Dr. Yasser Hassan Mohammed Hassan

Lecturer of Pediatrics

Faculty of Medicine - M.U.S.T. University

*Faculty of Medicine
Ain Shams University*

2017

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لسببائك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢



Acknowledgment

Firstly and lastly thanks to **ALLAH**
the most merciful for his help.

I would like to express my deepest gratitude and sincere appreciation to **Prof. Mohsen Saleh ElAlfy**, Professor of Pediatrics, Ain Shams University. I'm greatly thankful to him for his fatherly attitude, enthusiastic encouragement, his sincere advice, and supervision.

My extreme thanks and gratefulness to **Dr. Fatma Soliman Elsayed Ebeid** Lecturer of Pediatrics, Faculty of Medicine, Ain Shams University. She was very generous with her time and appreciable advice, which helped to simplify my hard task of preparing this work.

Also I would like to thank **Dr. Yasser Hassan Mohammed Hassan**, Lecturer of Pediatrics, Faculty of Medicine, M.U.S.T. University for his keen interest, beneficial advice, constant support and scientific opinions during the conduction of this work.

I wish to express my appreciation and sincere gratitude to **Dr. Eman Abdel Rahman Ismail** Consultant of Clinical Pathology, Clinical Pathology Department, Ain Shams University, for her kind help, indispensable advice and encouragement from the start of this work, Also for her sincere supervision and the endless effort that she had offered throughout the period of making and revising this thesis.

I am very grateful to **Dr. Deena Samir Eissa**, Assistant Professor of Clinical Pathology, Clinical Pathology Department, Ain Shams University, for her kind assistance and support.

Many grateful thanks to my parents for their continuing love, care and strong support, to whom I'm indebted for what I am today.

Finally, I'm grateful to the patients for whom all our efforts are devoted.

Aya Sayed

List of Contents

Title	Page No.
List of Tables	6
List of Figures	9
List of Abbreviations	13
Abstract	14
Introduction	2
Aim of the Work	4
Review of Literature	
Chapter (1): Overview of Sickle Cell Disease	5
Historical background	6
Prevalence & Epidemiology	8
Genetic Background	11
Pathophysiology of Sickle Cell Anemia	16
Clinical Picture of Sickle Cell Anemia	19
Prognosis	49
Management of SCD	51
Diagnosis of SCD	51
Treatment of Sickle Cell Disease	59
Chapter (2): Immunological Aspects of Sickle Cell Disease	82
CD4 ⁺ CD28 ^{null} T Lymphocytes	87
Prevalence in Healthy Humans and Patients	88
Functional Aspects of CD4 ⁺ CD28 ⁻ T cells	91
Interferon	95
IFN- γ Therapeutics	102
Subjects and Methods	105
Results	117
Discussion	143
Summary	155
Conclusion	158
Recommendations	159
References	160
Arabic summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Important discoveries in the pathological and clinical features of sickle-cell disease in chronological order	7
Table (2):	Gene frequency and common disease pattern of sickle cell haemoglobin (HbS) in the Middle Eastern Arab countries	11
Table (3):	Different types of sickle-cell disease	14
Table (4):	Symptomatology and clinical manifestations of vaso-occlusive crisis	23
Table (5):	Sickle cell trait (Hb A and Hb S)	27
Table (6):	Sickle cell anaemia (homozygous Hb S).....	27
Table (7):	Classification of renal manifestations of SCD based on described phenotypes.....	35
Table (8):	Acute bone problems in sickle cell disease	38
Table (9):	Chronic bone problems in sickle cell disease.....	40
Table (10):	Clinical Presentation of ACS:.....	48
Table (11):	Several emerging therapeutic approaches for treatment of sickle cell disease by mechanism.....	59
Table (12):	Recommended outpatient management of sickle-cell disease	61
Table (13):	Indications for transfusion therapy in sickle-cell disease	63
Table (14):	Beneficial erythrocyte and extra-erythrocyte effects of hydroxyurea treatment in homozygous HbSS disease.....	66
Table (15):	Baseline work-up required by the consulting hematologist before hydroxyurea treatment in SCD patients	70
Table (16):	Comparison of the 3 leading iron chelating drugs in the management of sickle cell anemia	75

List of Tables (cont...)

Table No.	Title	Page No.
Table (17):	HGNC- approved human interferon names.....	101
Table (18):	Interferons approved as biopharmaceuticals in the United States and Europe.....	103
Table (19):	Clinical data of the studied sickle cell disease patients	118
Table (20):	Disease characteristics of the studied sickle cell disease patients	119
Table (21):	Laboratory data and tissue iron overload by MRI among the studied sickle cell disease patients	120
Table (22):	Comparison of demographic data and anthropometric measures among patients and control group	121
Table (23):	Comparison of hematological and immunological data among SCD patients and control group	124
Table (24):	CD4 ⁺ T lymphocytes and CD4 ⁺ CD28 ^{null} T-cells in relation to clinical characteristics of sickle cell disease patients.....	127
Table (25):	Correlation between CD4 ⁺ T lymphocytes and CD4 ⁺ CD28 ^{null} T-cells and clinical, laboratory and MRI parameters of sickle cell disease patients.....	131
Table (26):	Multivariable linear regression analysis for variables related to increased CD4 ⁺ T lymphocytes in patients with sickle cell disease.....	136
Table (27):	Multivariable linear regression analysis for variables related to increased CD4 ⁺ CD28 ^{null} T-cells in patients with sickle cell disease.....	136

List of Tables (cont...)

Table No.	Title	Page No.
Table (28):	Interferon-gamma in relation to clinical characteristics of sickle cell disease patients.....	137
Table (29):	Correlation between interferon-gamma and clinical, laboratory and MRI parameters of sickle cell disease patients	140
Table (30):	Multivariable linear regression analysis for variables related to increased interferon-gamma in patients with sickle cell disease	142

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Peripheral blood smear of a patient with sickle-cell anemia	6
Figure (2):	The distribution of sickle-cell anemia haplotypes among nations with high prevalence of the disease	9
Figure (3):	Amino acid position 6 substitution in beta-hemoglobin chain	13
Figure (4):	Pathophysiology of vaso-occlusion in SCD.....	17
Figure (5):	Clinical implications and complications of sickle cell disease	21
Figure (6):	Shortened index finger of left hand and right middle finger as result of hand foot syndrome	24
Figure (7):	Child with sickle cell disease shows hair on end appearance on x-ray skull	31
Figure (8):	MRI brain shows cerebrovascular stroke in Child with sickle cell disease	32
Figure (9):	CT brain shows hemorrhagic stroke in SCD patient	33
Figure (10):	Pigmented gall stones in SCD patient	41
Figure (11):	Pathophysiology of hypercoagulable state and platelet activation in thalassaemia and sickle cell disease (SCD).....	43
Figure (12):	Pathophysiology of acute chest syndrome	47
Figure (13):	Survival of SCA patients	51
Figure (14):	Blood film shows irreversibly sickled cells	54
Figure (15):	Sites of desferal infusion	76
Figure (16):	Multicellular and multistep model of sickle cell vaso-occlusion.....	85

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (17):	Inflammation in SCD	86
Figure (18):	Phenotypic and functional features of CD4 ⁺ CD28 ⁻ T cells and their CD28 ⁺ counterparts	92
Figure (19):	The molecular structure of human interferon-alpha.....	95
Figure (20):	Flow cytometric analysis of CD4 ⁺ CD28 ^{null} T-cells in a patient with sickle cell disease.	112
Figure (21):	Weight SDS among patients with sickle cell disease compared with healthy control group.	122
Figure (22):	Height SDS among patients with sickle cell disease compared with healthy control group.	122
Figure (23):	BMI SDS among patients with sickle cell disease compared with healthy control group.	123
Figure (24):	WBCs and hemoglobin level in patients with sickle cell disease compared with healthy controls.	125
Figure (25):	Percentage of total lymphocytes and CD4 ⁺ lymphocytes among patients with sickle cell disease compared with healthy controls.	125
Figure (26):	CD4 ⁺ CD28 ^{null} total lymphocytes among patients with sickle cell disease compared with healthy controls.....	126
Figure (27):	Levels of IFN-gamma among patients with sickle cell disease compared with healthy controls.	126
Figure (28):	CD4 ⁺ T lymphocytes in relation to frequency of sickling crisis.....	129

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (29):	CD4+CD28 ^{null} T lymphocytes in relation to frequency of sickling crisis.	129
Figure (30):	CD4+CD28 ^{null} T lymphocytes among hydroxyurea-treated and untreated patients.....	130
Figure (31):	CD4+CD28 ^{null} T lymphocytes among patients on combined chelation and hydroxyurea therapy.....	130
Figure (32):	Significant positive correlation between CD4 ⁺ T lymphocytes and transfusion index among patients with sickle cell disease.....	132
Figure (33):	Significant positive correlation between CD4 ⁺ T lymphocytes and iron overload per day among patients with sickle cell disease.....	133
Figure (34):	Significant positive correlation between CD4+CD28 ^{null} T-cells and transfusion index among patients with sickle cell disease.....	133
Figure (35):	Significant positive correlation between CD4+CD28 ^{null} T-cells and iron overload among patients with sickle cell disease.	134
Figure (36):	Significant positive correlation between CD4+CD28 ^{null} T-cells and IFN-gamma among patients with sickle cell disease.	134
Figure (37):	Significant negative correlation between CD4+CD28 ^{null} T-cells and cardiac T2* among patients with sickle cell disease.	135
Figure (38):	Significant negative correlation between CD4+CD28 ^{null} T-cells duration of hydroxyurea among patients with sickle cell disease.	135

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (39):	IFN-gamma levels in relation to frequent sickling crisis.....	138
Figure (40):	IFN-gamma levels among hydroxyurea-treated and untreated patients.....	139
Figure (41):	IFN-gamma levels in relation to combined chelation and hydroxyurea therapy.....	139
Figure (42):	Significant negative correlation between IFN-gamma and cardiac T2* among patients with sickle cell disease.....	141
Figure (43):	Significant negative correlation between IFN-gamma and duration of hydroxyurea among patients with sickle cell disease.....	141

List of Abbreviations

Abb.	Full term
ACS.....	Acute chest syndrome
AVN	A vascular necrosis
FDA.....	Food and Drug Administration
Hb	Hemoglobin
HBB gene.....	Hemoglobin β - globin gene
HbF.....	Fetal hemoglobin
HbS.....	Sickle cell haemoglobin
HbSS.....	Hemoglobin SS
HPLC.....	High-performance liquid chromatography
HU	Hydroxyurea
IFN.....	Interferon gamma
IgM.....	Immunoglobulin M
NO.....	Nitric oxide
NSAIDs.....	Nonsteroidal anti-inflammatory agents
PAH	Pulmonary Hypertension
PS.....	Phosphatidylserine
RBCs.....	Red blood cells
ROS.....	Reactive oxygen species
SCA.....	Sickle cell anemia
SCD.....	Sickle cell disease
T lymphocytes.....	Thymus-derived lymphocytes
TCD.....	Transcranial Doppler
TRACP 5b.....	Tartrate-resistant acid phosphatase 5b
VCAM	Vascular cell-adhesion molecule
VOC	Vaso-occlusive crisis
VOE	Vaso-occlusive pain events
WBCs	White blood cells

Abstract

Background: Sickle cell disease (SCD) is increasingly appreciated as an inflammatory condition associated with alterations in immune phenotype and function. CD4⁺ T lymphocyte influence the functions of virtually all other cells of the immune system, including other T cells, B cells, macrophages and natural killer (NK) cells. CD4⁺CD28^{null} T-cells are a subset of long-lived directly cytotoxic CD4⁺ T lymphocytes that have pro-inflammatory functions characterized by the production of high levels of interferon-gamma (IFN-gamma). **Aim:** To assess the percentage of CD4⁺CD28^{null} T cells as well as IFN-gamma levels in 40 children and adolescents with SCD compared with 40 age- and sex-matched healthy controls and evaluate their relation to hemolysis, iron overload, vaso-occlusive crisis (>3 attacks/year) and response to therapy. **Methods:** SCD patients in steady state were studied focusing on history of frequent vaso-occlusive crisis, transfusion history, hydroxyurea therapy, hematological profile and serum ferritin. Analysis of T cells was done by flow cytometry for assessment of CD4⁺ T lymphocytes and CD4⁺CD28^{null} T-cells. Serum levels of interferon-gamma were assessed by enzyme linked immunosorbent assay (ELISA). **Results:** Patients with SCD had higher WBCs and lower hemoglobin level compared with controls. CD4⁺ T lymphocytes, CD4⁺CD28^{null} T-cells and IFN-gamma levels were significantly higher in patients than in controls. Patients with history of frequent sickling crisis had higher percentage of CD4⁺CD28^{null} T-cells and IFN-gamma than those without. The levels of these cells and IFN-gamma were significantly lower among hydroxyurea-treated patients as well as those on combined chelation and hydroxyurea therapy. There were significant positive correlations between each of CD4⁺ T lymphocytes and CD4⁺CD28^{null} T-cells and transfusion index and iron overload per day. Moreover, CD4⁺CD28^{null} T-cells were positively correlated to IFN-gamma while negatively correlated to cardiac T2* and duration of hydroxyurea therapy. A significant positive correlation was found between IFN-gamma and CD4⁺CD28^{null} T-cells while it was negatively correlated to cardiac T2* and duration of hydroxyurea. **Conclusions:** Expression of CD4⁺CD28^{null} T-cells with increased production IFN-gamma highlights the role of immune dysfunction in pediatric patients with SCD. Alteration of this subset of T lymphocytes is related to increased iron overload and higher incidence of vaso-occlusive crisis. Hydroxyurea and/or iron chelation therapy significantly contributes to the normalization of cytotoxic lymphocytes and attenuates immune dysfunction.

INTRODUCTION

Sickle cell anemia is a monogenic hemoglobinopathy wherein glutamic acid, the sixth amino acid in the β -globin chain, is displaced by valine. This results in hemoglobin polymerization and sickling morphology during hemoglobin desaturation. Clinically, the disease is characterized by chronic hemolysis, intermittent vaso-occlusive events, and organ injury (*Belcher et al., 2014*).

In sickle cell disease (SCD), hemoglobin molecules polymerize intracellularly and lead to a cascade of events resulting in decreased deformability and increased adhesion of red blood cells (RBCs). Decreased deformability and increased adhesion of sickle RBCs lead to blood vessel occlusion (vaso-occlusion) in SCD patients (*Alapan et al., 2016*).

SCD is a hypercoagulable state with chronic activation of coagulation and an increased incidence of thromboembolic events (*Whelihan et al., 2016*).

Patients with sickle cell anemia (HbSS), particularly children, have an increased susceptibility to infection leading to increased mortality. Opsonophagocytic defect due to an abnormality of the alternative complement pathway, deficiency of specific circulating antibodies, impaired leucocytes function and loss of both humoral and cell-mediated immunity are some of the other mechanisms that have been reported to account for

immunocompromised state in patients with sickle cell disease (*Ojo et al., 2014*).

Thymus-derived (T) lymphocytes play an important role in cellular immunity. In the blood, T lymphocytes constitute 60-70% of peripheral lymphocytes (*Hoffbrand et al., 2014*) and are also found in the paracortical areas of lymph nodes and periarteriolar sheath of the spleen. About 60% of mature T cells express CD4 (Helper) and 30% express CD8 (Cytotoxic). By secreting cytokines, CD4⁺ T lymphocyte influence the functions of virtually all other cells of the immune system, including other T cells, B cells, macrophages and natural killer cells (*Ojo et al., 2014*).

Studies have shown that patients with SCD have elevated white blood cells (WBCs) counts, absolute neutrophil count, total lymphocytes, monocytes, total T cells and total B cells. Total CD4⁺ T cells were also increased and this increase in CD4⁺ counts was more pronounced than SCD-associated increase in CD8⁺ count, the increase in total CD4⁺ T cell counts was driven by increases in all of the CD4⁺ T cell subpopulations (CD4⁺ T-naive, T-memory and T-regulatory), and was accompanied by increased number of proliferating (Ki67⁺) CD4⁺ T cells. In contrast, CD8⁺ T cells only demonstrated significant increase in memory (not naive) and proliferating T cells (*Robert et al., 2015*).